Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
September 18 2008 - 8:30AM
PR Newswire (US)
BOSTON, Sept. 18 /PRNewswire/ -- Scimitar Equity, LLC issues a
Q4/08 review of Neurobiological Technologies, Inc. (NASDAQ:NTII),
entitled, "Defining Outcome Scenarios, Probabilities Appear Focused
to the Upside and Future Appreciation." This review is available at
our website: http://www.scimitarequity.com/ Neurobiological
Technologies, Inc. (NTII) is a biotechnology company engaged in the
business of acquiring and developing central nervous system related
drug candidates. NTII is a specialty biopharmaceutical company with
expertise in identifying and acquiring promising drug candidates
and in designing and managing late-stage clinical trials for
central nervous system conditions. Neurobiological Technologies,
Inc. is currently developing Viprinex(TM) (ancrod), a novel
reperfusion agent that is in pivotal Phase 3 trials for the
treatment of acute ischemic stroke. For further information, please
visit NTII's website at http://www.ntii.com/ Scimitar Equity, LLC
provides sponsored equity research of emerging healthcare companies
for the investing communities. We certify that all the views
expressed in this review, accurately reflect our personal views
about NTII (NASDAQ) and its or their securities. Investors are
advised that this analysis and review is issued solely for
informational purposes and is not to be construed as an offer to
sell or the solicitation of an offer to buy. Scimitar was paid for
preparing this review. This analysis and review is based on sources
that we believe to be reliable but is not guaranteed by us as being
accurate and does not purport to be a complete statement or summary
of the available data. Any opinions expressed are statements of our
own judgment as of the date of publication and are subject to
change without notice. Please read all our important disclosures.
CONTACT: Scimitar Equity, LLC Henry W. McCusker Director of
Research phone: (617) 559.1080 e-mail: DATASOURCE: Scimitar Equity,
LLC CONTACT: Henry W. McCusker, Scimitar Equity, LLC, Director of
Research, +1-617-559-1080, Web site: http://www.scimitarequity.com/
http://www.ntii.com/
Copyright
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Jul 2024 to Aug 2024
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Aug 2023 to Aug 2024